Effect of Prednisolone Treatment on Uterine Natural Killer Cells
ConditionRecurrent Miscarriage
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorChinese University of Hong Kong
About this trial
This study aims to investigate the role of uNK cells and the association with prednisolone.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women with a history of 3 or more consecutive miscarriages
Women younger than 40 years old
Disqualifiers
Allergy to prednisolone
Women who have any uterine anomaly
Antiphospholipid syndrome
Hydrosalpinx
Trial design
Design model
Single group
Treatments tested in this trial
Prednisolone
Drugprednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
Treatment groups
84 Participants
are divided into 1 treatment groupGroup A: prednisoloneExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
the number of uNK cells
to investigate the association between uNK cells and prednisolone
Time frame
at the 1 day of endometrial biopsySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov